Docteur Guy BAUDENS

Bibliographie

• Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

  2024

  ArticleScientific Reports

• Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients with Rheumatoid Arthritis

  2022

  ArticleRheumatology International

• Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicenter Study

  2022

  ArticleFrontiers in Medicine

• Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

  2021

  ArticleRheumatology

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  2021

  ArticleRheumatology and Therapy

• Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

  2020

  ArticleJournal of Clinical Medicine

• Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

  2019

  ArticleRheumatology and Therapy

• Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life

  2017

  ArticleArthritis & rheumatology

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Low and stable prevalence of rheumatoid arthritis in northern France

  Joint bone spine · 2009

  📚 15 citations
• 2

  Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study

  Frontiers in medicine · 2022

  📚 14 citations🎯 RCR 1.93🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectivesPrevious studies demonstrated equivalence in terms of efficacy and safety of biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching situations. Less is known about what happens when initiating a bsDMARD in a molecule naïve patient. The objectives of our study were to compare the retention of treatment of subcutaneous boDMARDs and bsDMARDs globally, depending on the disease [rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic arthritis (PsA)], molecule [etanercept (ETN) or adalimumab (ADA)], line of treatment, or presence of citrate in the context of first use of each molecule (namely initiation) and to analyze treatment retention’s predictive factors.Materials and methodsThis multicenter retrospective study used data from shared medical records of the RIC-FRANCE network, encompassing the prescription of hospital rheumatologists and attached practitioners, of patients with RA, SpA, or PsA, with the starting ETN between 03/10/2016 and 31/07/2020, or ADA between 23/10/2018 and 31/07/2020. Clinical data were collected from medical records. Retention analysis was performed using Kaplan–Meier curves and the log-rank test. Retention’s predictive factors were analyzed using Cox proportional-hazard ratio.ResultsEight hundred forty-five prescriptions were analyzed: 340 boDMARDs and 505 bsDMARDs. About 57% of prescriptions concerned women. The mean age was 51.8 years. About 38% were prescriptions for RA, 16% for PsA, and 46% for SpA. An increase in the initiation over time was observed for both ETN and ADA. The retention rate of bsDMARDs was superior to boDMARDs’ one (39 vs. 23 months; p = 0.045). When molecules are compared, the difference was significant only for ETN (45 vs. 19 months for boDMARD; p = 0.0265). When comparing diseases, the difference in favor of bsDMARDs was significant in patients with RA only (p = 0.041). Citrated treatments displayed better retention compared to citrate-free treatments (p = 0.0137). Multivariable analysis of predictive factors for the cessation of treatment found shorter disease duration, boDMARD prescription, hospital practitioner prescription, late line of treatment, and female sex as significant. More side effects were observed with boDMARDs, especially more infections (17.8% vs. 7.8%).ConclusionEven if bsDMARDs’ prescription increases over time, its penetration rate is still below expectations. bsDMARDs displayed better retention compared to boDMARDs, especially for ETN, and in patients with RA. Citrated treatments had better retention. Prescription by a full-time hospital-based rheumatologist is associated with poorer retention.

• 3

  Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

  Rheumatology (Oxford, England) · 2021

  📚 12 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected. Results A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts. Conclusion In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.

Publications scientifiques (10) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  Audiovisual2020Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  Audiovisual2020Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online

• Tocilizumab Effectiveness after Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis - The RoSwitch Study

  Image2019Adis Journals

  Full copyright for enhanced digital features is owned by the authors. <strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>. <br> <br> <strong>Provide enhanced digital features fo

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche